Klotho and phosphate are modulators of pathologic uremic cardiac remodeling

Journal of the American Society of Nephrology

Volumn 26, Issue 6, 2015, Pages 1290-1302

  Hu, Ming Chang ^a,b   Shi, Mingjun ^a   Cho, Han Jun ^a   Adams Huet, Beverley ^a,b,c   Paek, Jean ^a   Hill, Kathy ^a   Shelton, John ^b   Amaral, Ansel P ^d   Faul, Christian ^d   Taniguchi, Masatomo ^a,c   Wolf, Myles ^d,f   Brand, Markus ^e   Takahashi, Masaya ^c   Kuro o, Makoto ^a,b   Hill, Joseph A ^b,c   Moe, Orson W ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTININ; ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; COLECALCIFEROL; COLLAGEN TYPE 1; CREATININE; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PARATHYROID HORMONE; PHOSPHATE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; BETA GLUCURONIDASE; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

AGING; ANIMAL CELL; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HEART DISEASE; HEART FIBROBLAST; HEART FUNCTION; HEART INJURY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; MOUSE; NEWBORN; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; UNINEPHRECTOMY; UPREGULATION; UREMIA; UREMIC CARDIAC REMODELING; VITAMIN BLOOD LEVEL; ANIMAL; BLOOD; CARDIOMEGALY; CELL CULTURE; COMPARATIVE STUDY; DISEASE MODEL; FIBROBLAST; FIBROSIS; GENETICS; HEART FUNCTION TEST; HEART VENTRICLE REMODELING; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; RENAL INSUFFICIENCY, CHRONIC; SENSITIVITY AND SPECIFICITY; TRANSGENIC MOUSE;

ANIMALS; BIOMARKERS; CARDIOMEGALY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTORS; FIBROBLASTS; FIBROSIS; GLUCURONIDASE; HEART FUNCTION TESTS; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; PHOSPHATES; RANDOM ALLOCATION; RENAL INSUFFICIENCY, CHRONIC; SENSITIVITY AND SPECIFICITY; UREMIA; VENTRICULAR REMODELING;

EID: 84930436563     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014050465     Document Type: Article

References (71)

1. Mizobuchi M, Towler D, Slatopolsky E: Vascular calcification: The killer of patients with chronic kidney disease. J Am Soc Nephrol 20: 1453-1464, 2009
2. Stack AG, Bloembergen WE: Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: A cross-sectional study. J Am Soc Nephrol 12: 1516-1523, 2001
3. Rössle R: Über die serösen Entzündugen der Organe. Virchows Arch 311: 252-284, 1943
4. Tyralla K, Amann K: Morphology of the heart and arteries in renal failure. Kidney Int Suppl 84: S80-S83, 2003
5. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47: 186-192, 1995
6. Bakkaloglu SA, Borzych D, Soo Ha I, Serdaroglu E, Büscher R, Salas P, Patel H, Drozdz D, Vondrak K, Watanabe A, Villagra J, Yavascan O, Valenzuela M, Gipson D, Ng KH, Warady BA, Schaefer F; International Pediatric Peritoneal Dialysis Network: Cardiac geometry in children receiving chronic peritoneal dialysis: Findings from the International Pediatric Peritoneal Dialysis Network (IPPN) registry. Clin J Am Soc Nephrol 6: 1926-1933, 2011
7. Foley RN, Curtis BM, Randell EW, Parfrey PS: Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol 5: 805-813, 2010
8. Park M, Hsu CY, Li Y, Mishra RK, Keane M, Rosas SE, Dries D, Xie D, Chen J, He J, Anderson A, Go AS, Shlipak MG; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol 23: 1725-1734, 2012
9. Mall G, Huther W, Schneider J, Lundin P, Ritz E: Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 5: 39-44, 1990
10. Aoki J, Ikari Y, Nakajima H, Mori M, Sugimoto T, Hatori M, Tanimoto S, Amiya E, Hara K: Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Int 67: 333-340, 2005
11. Martin FL, McKie PM, Cataliotti A, Sangaralingham SJ, Korinek J, Huntley BK, Oehler EA, Harders GE, Ichiki T, Mangiafico S, Nath KA, Redfield MM, Chen HH, Burnett JC Jr.: Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: A kidney-heart connection. Am J Physiol Regul Integr Comp Physiol 302: R292-R299, 2012
12. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP: Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet 382: 339-352, 2013
13. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51, 1997
14. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-o M: Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 282: 26687-26695, 2007
15. Kim J, Eskiocak U, Stadler G, Lou Z, Kuro-o M, Shay JW, Wright WE: Short hairpin RNA screen indicates that Klotho beta/FGF19 protein overcomes stasis in human colonic epithelial cells. J Biol Chem 286: 43294-43300, 2011
16. Ito S, Fujimori T, Hayashizaki Y, Nabeshima Y: Identification of a novel mouse membrane-bound family 1 glycosidase-like protein, which carries an atypical active site structure. Biochim Biophys Acta 1576: 341-345, 2002
17. Hu MC, Shiizaki K, Kuro-o M, Moe OW: Fibroblast growth factor 23 and Klotho: Physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 75: 503-533, 2013
18. Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, Shi M, Eliseenkova AV, Razzaque MS, Moe OW, Kuro-o M, Mohammadi M: Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci USA107: 407-412, 2010
19. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M: Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281: 6120-6123, 2006
20. Razzaque MS, Lanske B: The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol194: 1-10, 2007
21. Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR: Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci U S A 104: 19796-19801, 2007
22. Bloch L, Sineshchekova O, Reichenbach D, Reiss K, Saftig P, Kuro-o M, Kaether C: Klotho is a substrate for alpha-, beta- and gamma-secretase. FEBS Lett 583: 3221-3224, 2009
23. Massy ZA, Drüeke TB: Vascular calcification. Curr Opin Nephrol Hypertens 22: 405-412, 2013
24. Kuro-o M: Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol 9: 650-660, 2013
25. Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S, Serra AL: Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: A sequence suggested from a cross-sectional study. Nephrol Dial Transplant 28: 352-359, 2013
26. Hu MC, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-o M, Moe OW: Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 22: 124-136, 2011
27. Kitagawa M, Sugiyama H, Morinaga H, Inoue T, Takiue K, Ogawa A, Yamanari T, Kikumoto Y, Uchida HA, Kitamura S, Maeshima Y, Nakamura K, Ito H, Makino H: A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PLoS ONE 8: e56695, 2013
28. Lau WL, Leaf EM, Hu MC, Takeno MM, Kuro-o M, Moe OW, Giachelli CM: Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 82: 1261-1270, 2012
29. Lim K, Lu TS, Molostvov G, Lee C, Lam FT, Zehnder D, Hsiao LL: Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 125: 2243-2255, 2012
30. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-4408, 2011
31. Xie J, Cha SK, An SW, Kuro-O M, Birnbaumer L, Huang CL: Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat Commun 3: 1238, 2012
32. Takeshita K, Fujimori T, Kurotaki Y, Honjo H, Tsujikawa H, Yasui K, Lee JK, Kamiya K, Kitaichi K, Yamamoto K, Ito M, Kondo T, Iino S, Inden Y, Hirai M, Murohara T, Kodama I, Nabeshima Y: Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression. Circulation 109: 1776-1782, 2004
33. Rhyu DY, Yang Y, Ha H, Lee GT, Song JS, Uh ST, Lee HB: Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol 16: 667-675, 2005
34. Olson ER, Naugle JE, Zhang X, Bomser JA, Meszaros JG: Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. Am J Physiol Heart Circ Physiol 288: H1131-H1138, 2005
35. House SL, House BE, Glascock B, Kimball T, Nusayr E, Schultz JE, Doetschman T: Fibroblast growth factor 2 mediates isoproterenol-induced cardiac hypertrophy through activation of the extracellular regulated kinase. Mol Cell Pharmacol 2: 143-154, 2010
36. Hu MC, Kuro-o M, Moe OW: Klotho and chronic kidney disease. Contrib Nephrol 180: 47-63, 2013
37. Bansal N, Keane M, Delafontaine P, Dries D, Foster E, Gadegbeku CA, Go AS, Hamm LL, Kusek JW, Ojo AO, Rahman M, Tao K, Wright JT, Xie D, Hsu CY; CRIC Study Investigators: A longitudinal study of left ventricular function and structure from CKD to ESRD: The CRIC study. Clin J Am Soc Nephrol 8: 355-362, 2013
38. Smith RC, O'Bryan LM, Farrow EG, Summers LJ, Clinkenbeard EL, Roberts JL, Cass TA, Saha J, Broderick C, Ma YL, Zeng QQ, Kharitonenkov A, Wilson JM, Guo Q, Sun H, Allen MR, Burr DB, Breyer MD, White KE: Circulating αKlotho influences phosphate handling by controlling FGF23 production. J Clin Invest 122: 4710-4715, 2012
39. Brownstein CA, Adler F, Nelson-Williams C, Iijima J, Li P, Imura A, Nabeshima Y, Reyes-Mugica M, Carpenter TO, Lifton RP: A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U S A 105: 3455-3460, 2008
40. Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, Shiizaki K, Gotschall R, Schiavi S, Yorioka N, Takahashi M, Boothman DA, Kuro-o M: Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 286: 8655-8665, 2011
41. Satoh M, Nagasu H, Morita Y, Yamaguchi TP, Kanwar YS, Kashihara N: Klotho protects against mouse renal fibrosis by inhibiting Wnt signaling. Am J Physiol Renal Physiol 303: F1641-F1651, 2012
42. Zhou L, Li Y, Zhou D, Tan RJ, Liu Y: Loss of Klotho contributes to kidney injury by derepression of Wnt/β-catenin signaling. J Am Soc Nephrol 24: 771-785, 2013
43. Sugiura H, Yoshida T, Shiohira S, Kohei J, Mitobe M, Kurosu H, Kuro-o M, Nitta K, Tsuchiya K: Reduced Klotho expression level in kidney aggravates renal interstitial fibrosis. Am J Physiol Renal Physiol 302: F1252-F1264, 2012
44. Mitani H, Ishizaka N, Aizawa T, Ohno M, Usui S, Suzuki T, Amaki T, Mori I, Nakamura Y, Sato M, Nangaku M, Hirata Y, Nagai R: In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension 39: 838-843, 2002
45. de Boer RA, Pokharel S, Flesch M, van Kampen DA, Suurmeijer AJ, Boomsma F, van Gilst WH, van Veldhuisen DJ, Pinto YM: Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2) 27. J Mol Med (Berl) 82: 678-687, 2004
46. Bowers SL, Borg TK, Baudino TA: The dynamics of fibroblast-myocyte-capillary interactions in the heart. Ann N Y Acad Sci 1188:143-152,2010
47. Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L, Wakimoto H, Nayor M, Konno T, Gorham JM, Wolf CM, Kim JB, Schmitt JP, Molkentin JD, Norris RA, Tager AM, Hoffman SR, Markwald RR, Seidman CE, Seidman JG: Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest 120: 3520-3529, 2010
48. Fredj S, Bescond J, Louault C, Potreau D: Interactions between cardiac cells enhance cardiomyocyte hypertrophy and increase fibroblast proliferation. J Cell Physiol 202: 891-899, 2005
49. Brown RD, Ambler SK, Mitchell MD, Long CS: The cardiac fibroblast: Therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 45: 657-687, 2005
50. Vasquez C, Benamer N, Morley GE: The cardiac fibroblast: Functional and electrophysiological considerations in healthy and diseased hearts. J Cardiovasc Pharmacol 57: 380-388, 2011
51. Roberts PR, Green D: Arrhythmias in chronic kidney disease. Heart 97: 766-773, 2011
52. Shamseddin MK, Parfrey PS: Sudden cardiac death in chronic kidney disease: Epidemiology and prevention. Nat Rev Nephrol 7: 145-154, 2011
53. Razzaque MS: Phosphate toxicity and vascular mineralization. Contrib Nephrol 180: 74-85, 2013
54. Martin KJ, González EA: Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: What is normal, when to start, and how to treat? Clin J Am Soc Nephrol 6: 440-446, 2011
55. Zoccali C, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, Mallamaci F, Remuzzi G; REIN Study Group: Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 22: 1923-1930, 2011
56. Hayashi SY, Rohani M, Lindholm B, Brodin LA, Lind B, Barany P, Alvestrand A, Seeberger A: Left ventricular function in patients with chronic kidney disease evaluated by colour tissue Doppler velocity imaging. Nephrol Dial Transplant 21: 125-132, 2006
57. Levin A, Li YC: Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 68: 1973-1981, 2005
58. Mancuso P, Rahman A, Hershey SD, Dandu L, Nibbelink KA, Simpson RU: 1,25-Dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone (cp/+) rats independent of changes in serum leptin. J Cardiovasc Pharmacol 51: 559-564, 2008
59. Wan M, Smith C, Shah V, Gullet A, Wells D, Rees L, Shroff R: Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease. Nephrol Dial Transplant 28: 153-161, 2013
60. Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, Kagawa T, Inoue M, Fujimoto S, Ikebe M, Yuasa K, Yamanaka S, Sugiura T, Terada Y: Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Clin Exp Nephrol 16: 722-729, 2012
61. Ky B, Shults J, Keane MG, Sutton MS, Wolf M, Feldman HI, Reese PP, Anderson CA, Townsend RR, Deo R, Lo J, Gadegbeku C, Carlow D, Sulik MJ, Leonard MB; CRIC Study Investigators: FGF23 modifies the relationship between vitamin D and cardiac remodeling. Circ Heart Fail 6: 817-824, 2013
62. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE: Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207: 546-551, 2009
63. Shibata K, Fujita S, Morita H, Okamoto Y, Sohmiya K, Hoshiga M, Ishizaka N: Association between circulating fibroblast growth factor 23, α-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. PLoS ONE 8: e73184, 2013
64. Nakatani T, Sarraj B, Ohnishi M, Densmore MJ, Taguchi T, Goetz R, Mohammadi M, Lanske B, Razzaque MS: In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis. FASEB J 23: 433-441, 2009
65. Nakatani T, Ohnishi M, Razzaque MS: Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. FASEB J 23: 3702-3711, 2009
66. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR, Rosenblatt KP, Kuro-o M: Suppression of aging in mice by the hormone Klotho. Science 309: 1829-1833, 2005
67. Hu MC, Bankir L, Michelet S, Rousselet G, Trinh-Trang-Tan MM: Massive reduction of urea transporters in remnant kidney and brain of uremic rats. Kidney Int 58: 1202-1210, 2000
68. Aoyagi T, Kusakari Y, Xiao CY, Inouye BT, Takahashi M, Scherrer-Crosbie M, Rosenzweig A, Hara K, Matsui T: Cardiac mTOR protects the heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 303: H75-H85, 2012
69. Yund EE, Hill JA, Keller RS: Hic-5 is required for fetal gene expression and cytoskeletal organization of neonatal cardiac myocytes. J Mol Cell Cardiol 47: 520-527, 2009
70. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN: Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 105: 13027-13032, 2008
71. Kato Y, Arakawa E, Kinoshita S, Shirai A, Furuya A, Yamano K, Nakamura K, Iida A, Anazawa H, Koh N, Iwano A, Imura A, Fujimori T, Kuro-o M, Hanai N, Takeshige K, Nabeshima Y: Establishment of the anti-Klotho monoclonal antibodies and detection of Klotho protein in kidneys. Biochem Biophys Res Commun 267: 597-602, 2000